Skip to Content

Encorafenib (Braftovi®) + Cetuximab (Erbitux®) + mFOLFOX6 for BRAF V600E-Positive Metastatic Colorectal Cancer

Download PQI pdf 0.27MB

Last Updated: June 27, 2025

By: Jennah Bauernfeind, PharmD, BCOP

About this PQI

The purpose of this PQI is to review clinical considerations related to the use of encorafenib combined with cetuximab and mFOLFOX6 (EC + mFOLFOX6) in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI